



Supplementary Figure S1. *Ptpn22* deficiency increases the frequency and activation of antigen experienced cells in dLNs and spleens of anti-PD-L1 treated mice. WT or *Ptpn22*^{-/-} mice were inoculated with MC38 tumor cells. Upon tumor establishment, mice were treated with anti-PD-L1 or isotype control antibody and tissues were collected on day 9 post-treatment. **A.** Number of CD4⁺ T cells in dLNs. **B.** Frequency of CD4⁺ T cell subsets in dLNs of tumor bearing mice. **C.** Frequency of CD8⁺ and **D.** CD4⁺ T cell subsets in spleens of tumor bearing mice. **E.** Frequency of CXCR3 and ICOS expressing CD8⁺ and CD4⁺ T cells in spleens of tumor bearing mice. *n* = 4-8 mice/group. Data are mean ± SD. *P* values determined by using non-parametric, Mann-Whitney tests. * *P* < 0.05, ** *P* < 0.01.